Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions

Moriya, Takuya; Kanomata, Naoki; Kikuchi, Yuji; Fukumoto, Motoi; Iwachido, Nobuhisa; Hata, Sakae; Takahashi, Yayoi; Miura, Hidekazu; Ishida, Kazuyuki; Watanabe, Mika

doi:10.1007/s12282-009-0127-7

Cited by 22 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuroendocrine (NE) expression in IHC through NE markers represents the gold standard for diagnosing primary SCNC; chromogranin A, chromogranin B, and synaptophysin are considered the most sensitive and specific NE markers for this condition 11. The expression of NE markers is not consistent in the very rare SCNC of the breast subtype, however 8,12.…”

Section: Discussionmentioning

confidence: 99%

Primary small-cell neuroendocrine carcinoma of the male breast: a rare case report with review of the literature

Jiang¹,

Wang²,

Li³

et al. 2014

OTT

View full text Add to dashboard Cite

In this case study and review, we present a case of a primary small-cell neuroendocrine carcinoma (SCNC) of the male breast. Primary SCNC of the breast is a rare tumor with less than 30 cases reported in the literature. Most cases are found in women. Another exceptional point is that human epidermal growth factor receptor-2 (Her-2) immunoreactivity was positive in our recent case, which differed to previous reports detailing SCNC in women. We have no evidence to demonstrate the differences between treatment and prognoses for males and females, because we do not have sufficient cases to undertake an evidence-based investigation. We provide this rare case history; review the literature on SCNC of the breast; and discuss detailed information regarding epidemiology, histogenesis, clinical and histologic diagnosis criteria, surgical and adjuvant treatment, and prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary small-cell neuroendocrine carcinoma of the male breast: a rare case report with review of the literature

Jiang¹,

Wang²,

Li³

et al. 2014

OTT

View full text Add to dashboard Cite

show abstract

“…The overall accuracy increased from 84.5 to 92.8%. Moreover, Moriya et al suggested that certain immunohistochemical markers are quite useful in diagnosing various breast lesions, particularly for separating benign lesions and malignant neoplasms; however, the situations in which these markers are valuable are not universal, and their application and methods for evaluation are limited (26). Ultimately, 5 papillary lesions (16%) initially diagnosed as benign papillary lesions were diagnosed as a breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Papillary lesions of the breast diagnosed using core needle biopsies

Tokiniwa

Horiguchi

Takata

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Papillary lesions of the breast include a broad spectrum of lesions, from benign papillomas to papillary carcinomas. It is difficult to determine whether a lesion is benign or malignant based on the fragmented material of a core needle biopsy (CNB). This study evaluated patients with papillary lesions examined using CNB. We retrospectively reviewed 31 papillary lesions diagnosed using CNB between 2004 and 2007. The clinical findings of benign and malignant papillary lesions were compared. The average patient age was 48.9 years. Twelve patients presented with a discharge and 10 patients presented with a lump. Eight patients were asymptomatic. The initial diagnoses by CNB of the 31 lesions were 25 intraductal papillomas, 4 intracystic papillomas and 2 adenomas. After CNB, excisional biopsies were performed in 23 patients and biopsies with a Mammotome ® in 2 patients. Seven patients underwent regular follow-up. Five (16%) of the 31 patients with papillary lesions were ultimately diagnosed with breast cancer. The average distance from the nipple to a tumor diagnosed as malignant was 2.46 cm, which was longer than for a tumor diagnosed as benign. Ultimately, 5 papillary lesions (16%) were diagnosed as breast cancer. To avoid overlooking a malignancy, surgical excision is advantageous for papillary lesions, particularly those located far from the nipple.

show abstract

“…Immunohistochemical stains, such as p63, actin, calponin, can facilitate the recognition of myoepithelial cells; thus, they are useful in differentiating EPC from other breast papillary lesions. [22] When neoplastic epithelial elements infiltrate beyond the surrounding fibrous capsule, frank invasive carcinoma is diagnosed and this should be differentiated both from entrapment of neoplastic cells in the fibrous capsule and from their displacement into a previous biopsy tract. The absence of myoepithelial cells at the lesion periphery has been interpreted as revealing a minimally invasive form of carcinoma, [17,23] or according to other investigators, a form of carcinoma "in transition" between in situ and invasive carcinoma.…”

Section: Mulligan and O'malleymentioning

confidence: 99%

Encapsulated papillary carcinoma of the breast: An overview

et al. 2013

View full text Add to dashboard Cite

Any papillary growth of the breast presents both a diagnostic and a therapeutic challenge: For each one of them a diagnosis of whether they are malignant or benign in nature is required as well as appropriate staging and suitable treatment. In the international literature, we find a considerable amount of different terms being used for papillary breast growths. As a result, pathological and clinical evaluation is somewhat problematic. Encapsulated papillary carcinoma (EPC) is an interesting subgroup of breast papillary tumours. Because of its rarity, there have been only a limited number of large clinical studies that safely assess its appropriate treatment and expected outcome. However, more safe data exist in terms of prognosis - which seems to be excellent, as almost all published studies regarding these tumours have confirmed so far. We present a systematic overview of breast EPC and of the most important studies published on this topic in order to make diagnosis and treatment more straightforward for cancer clinicians. The information for this review was compiled by searching the Pubmed, Medline, Scopus, Embase, and ISI Web of Science databases for articles published from 1980 through December 2012. Electronic early-release publications were also included.

show abstract

Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions

Cited by 22 publications

References 20 publications

Primary small-cell neuroendocrine carcinoma of the male breast: a rare case report with review of the literature

Primary small-cell neuroendocrine carcinoma of the male breast: a rare case report with review of the literature

Papillary lesions of the breast diagnosed using core needle biopsies

Encapsulated papillary carcinoma of the breast: An overview

Contact Info

Product

Resources

About